Improved Monoclonal Antibodies Against Neuregulin 2
Posted Nov 05 2012 7:00pm
Description of Invention: The invention provides highly selective monoclonal antibodies against the extracellular domain (ECD) or intracellular domain (ICD) of neuregulin-2, a ligand for the ErbB receptors in adult human brain. Neuregulins regulate a diverse array of neurological process in the central nervous system and are implicated in schizophrenia and other psychiatric disorders. However, an understanding of the specific role of neuregulin 2 has been hindered by a lack of specific antibodies useful in immunoblotting and immunohistology studies. Commercially available antibodies do not perform as well in these applications when compared to the invention antibodies. A mouse monoclonal antibody directed to the ECD is available for licensing (clone 8D11, HHS Ref. No. E-192-2012), and rabbit antibodies directed to the ICD are also available (clone 11-11, HHS Ref. No. E-193-2012; clone 15-10, HHS Ref. No. E-189-2012; and clone 9-2, HHS Ref. No. E-188-2012). Antibodies from clones 8D11 and 11-11 have been validated for immunohistology and antibodies from clones 15-10 and 9-2 have been validated for Western blotting using brain tissue from wild-type and neuregulin 2 deficient mice.
Applications: Superior monoclonal antibody for Western blotting or immunohistology analysis of tissue sections
Superior binding specificity in comparison to commercially available antibodies
Developed antibodies bind specific, characterized regions on neuregulin 2
In vitro data available
Inventors: Detlef Vullhorst (NICHD) Andres L Buonanno (NICHD) Irina D Karavanov (NICHD)
This is a Research Tool — patent protection is not being pursued for this technology.
Collaborative Research Opportunity: The NICHD is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize neuregulin-2 monoclonal antibodies. For collaboration opportunities, please contact Charlotte McGuinness at firstname.lastname@example.org .